Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 221-225

  Stoehlmacher, Jan ^a   Goekkurt, Eray ^a   Mogck, Ulrike ^a   Aust, Daniela E ^a   Kramer, Michael ^a   Baretton, Gustavo B ^a   Liersch, Torsten ^b   Ehninger, Gerhard ^a   Jakob, Christiane ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Rectal Cancer; TS polymorphism

Indexed keywords

FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECTUM CANCER; TS GENE;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECTAL NEOPLASMS; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 55949090530     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.008     Document Type: Article

References (15)

1. Sauer R., Becker H., Hohenberger W., Rödel C., Wittekind C., Fietkau R., Martus P., Tschmelitsch J., Hager E., Hess C.F., Karstens J.H., Liersch T., Schmidberger H., and Raab R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351 (2004) 1731-1740
2. Minsky B.D., Cohen A.M., Kemeny N., Enker W.E., Kelsen D.P., Reichman B., Saltz L., Sigurdson E.R., and Frankel J. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J. Clin. Oncol. 10 (1992) 79-84
3. Moertel C.G. Chemotherapy for colorectal cancer. N. Engl. J. Med. 330 (1994) 1136-1142
4. Mandola M.V., Stoehlmacher J., Muller-Weeks S., Cesarone G., Yu M.C., Lenz H.J., and Ladner R.D. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63 (2003) 2898-2904
5. Kawakami K., and Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63 (2003) 6004-6007
6. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1 (2001) 65-70
7. Mandola M.V., Stoehlmacher J., Zhang W., Groshen S., Yu M.C., Iqbal S., Lenz H.J., and Ladner R.D. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
8. Jakob C., Aust D.E., Meyer W., Baretton G.B., Schwabe W., Häusler P., Becker H., and Liersch T. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J. Pathol. 204 (2004) 562-568
9. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., and Stoehlmacher J. Polymorphisms of glutathione-S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94 (2006) 281-286
10. Leichman C.G., Lenz H.J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., and Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15 (1997) 3223-3229
11. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., and Danenberg P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6 (2000) 1322-1327
12. Dotor E., Cuatrecases M., Martínez-Iniesta M., Navarro M., Vilardell F., Guinó E., Pareja L., Figueras A., Molleví D.G., Serrano T., de Oca J., Peinado M.A., Moreno V., Germà J.R., Capellá G., and Villanueva A. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J. Clin. Oncol. 24 (2006) 1603-1611
13. Negri F.V., Campanini N., Camisa R., Pucci F., Bui S., Ceccon G., Martinelli R., Fumagalli M., Losardo P.L., Crafa P., Bordi C., Cascinu S., and Ardizzoni A. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br. J. Cancer 98 (2008) 143-147
14. Rödel C., Martus P., Papadoupolos T., Füzesi L., Klimpfinger M., Fietkau R., Liersch T., Hohenberger W., Raab R., Sauer R., and Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 23 (2005) 8688-8696
15. McLeod H., Tan B., Malyapa R., Abbey E., Picus J., Myerson R., Zehnbauer B., Mutch M., Dietz D., and Fleshman J. Genotype guided neoadjuvant therapy for rectal cancer. J. Clin. Oncol. 23 16S (2005) 3024